Drugs Xagena
A multicenter, randomized, double-blind, placebo-controlled, active-referenced ( Duloxetine 60 mg ), parallel-group study evaluated the short-term efficacy and safety of Vortioxetine ( 10-20 mg ) [ Br ...
The European Commission ( EC ) has approved Revlimid ( Lenalidomide ) for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The Revlimi ...
The European Commission has approved the use of Xadago ( Safinamide ) for the treatment of idiopathic Parkinson’s disease. Xadago has been approved for mid-to late-stage fluctuating patients as add- ...
The FDA ( Food and Drug Administration ) has granted approval to Lenvima ( Lenvatinib ) to treat patients with progressive, differentiated thyroid cancer ( DTC ) whose disease progressed despite recei ...
Ther FDA ( Food and Drug Administration ) has granted accelerated approval to Rucaparib ( Rubraca ) for treatment of patients with deleterious BRCA mutation ( germline and/or somatic ) associated adva ...
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) issued positive opinions recommending marketing authorization for three of its pipeline development ...
The FDA ( Food and Drug Administration ) has granted accelerated approval to Ibrance ( Palbociclib ) to treat advanced ( metastatic ) breast cancer. Breast cancer in women is the second most common ...
The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion for Abraxane ( Paclitaxel formulated as albumin-bound nanoparticles, or N ...
The European Commission ( EC ) has granted marketing authorisation for Otezla ( Apremilast ), an oral selective inhibitor of phosphodiesterase 4 ( PDE4 ), in two therapeutic indications: A) For the t ...
The European Commission ( EC ) has approved Cosentyx ( Secukinumab ) as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. Cos ...
< br>The European Commission ( EC ) has granted marketing authorizations for Abbvie's all-oral, short-course, Interferon-free treatment of Viekirax ( Ombitasvir / Paritaprevir / Ritonavir tablet ...
The FDA ( Food and Drug Administration ) has approved the anti-clotting drug Savaysa ( Edoxaban tablets ) to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation that i ...
The U.S. Food and Drug Administration ( FDA ) has approved Belsomra ( Suvorexant ) tablets for use as needed to treat difficulty in falling and staying asleep ( insomnia ). Belsomra is an orexin re ...
Many patients treated with statins are considered statin-resistant because they fail to achieve adequate reduction of low density lipoprotein cholesterol ( LDL-C ) levels. Some patients are statin-i ...
The FDA ( Food and Drug Administration ) has approved Saxenda ( Liraglutide [ rDNA origin ] injection ) as a treatment option for chronic weight management in addition to a reduced-calorie diet and ph ...
The FDA ( Food and Drug Administration ) has approved Xtoro ( Finafloxacin otic suspension ), a new drug used to treat acute otitis externa, commonly known as swimmer’s ear. Acute otitis externa is ...
The FDA ( Food and Drug Administration ) has granted accelerated approval for Blincyto ( Blinatumomab ) for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor ac ...
Duaklir Genuair ( Aclidinium bromide / Formoterol fumarate 340/12 mcg ) has been granted marketing authorisation by the European Commission ( EC ) to be used as a maintenance bronchodilator treatment ...
The European Commission has granted EU marketing authorisation for Vargatef ( Nintedanib ). Vargatef in combination with Docetaxel ( Taxotere ) is indicated for use in adult patients with locally adva ...
The FDA ( Food and Drug Administration ) has granted accelerated approval to Lynparza ( Olaparib ), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as ...
The FDA ( Food and Drug Administration ) has granted accelerated approval to Opdivo ( Nivolumab ), a new treatment for patients with unresectable ( cannot be removed by surgery ) or metastatic ( advan ...
The European Commission ( EC ) has approved Cometriq ( Cabozantinib ) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma ( MT ...
The FDA ( Food and Drug Administration ) has approved Viekira Pak ( Ombitasvir, Paritaprevir and Ritonavir tablets co-packaged with Dasabuvir tablets ) to treat patients with chronic hepatitis C virus ...
The FDA ( Food and Drug Administration ) has approved Hysingla ER ( Hydrocodone bitartrate ), an extended-release ( ER ) opioid analgesic to treat pain severe enough to require daily, around-the-clock ...
The European Commission has granted marketing authorization for Harvoni ( Ledipasvir 90 mg / Sofosbuvir 400 mg ), the first once-daily single tablet regimen to treat the majority of chronic hepatitis ...
The FDA ( Food and Drug Administration ) has granted Breakthrough Therapy Designation to Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Re ...
Liraglutide is a human glucagon-like peptide 1 analog that may be administered once a day because of its prolonged half-life of 13 hours. Liraglutide was developed to improve glycemic control in p ...
A FDA ( Food and Drug Administration ) study of more than 134,000 Medicare patients found that Pradaxa ( Dabigatran etexilate mesylate ) was associated with significantly reduced risks of ischemic str ...
The European Commission has approved Imbruvica ( Ibrutinib ) capsules, a first-in-class, once-daily, oral Bruton's tyrosine kinase ( BTK ) inhibitor. Ibrutinib works by blocking BTK, a protein that ...
The FDA ( Food and Drug Administration ) has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio ( Teriflunomide ) in the product’s U.S. lab ...
The Food and Drug Administration ( FDA ) has approved Otezla ( Apremilast ), oral, selective inhibitor of phosphodiesterase 4 ( PDE4 ), for the treatment of patients with moderate to severe plaque pso ...
The FDA ( Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for treatment of patients with advanced or unresectable melanoma who are no longer responding to ...
The European Commission has granted marketing authorization for Zydelig ( Idelalisib ), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers, chronic lymphocytic leukemia ( ...
RPC1063 is a novel, oral, once daily, specific and potent modulator of the sphingosine 1-phosphate 1 receptor ( S1P1R ) pathway, which is a validated G protein-coupled receptor ( GPCR ) target for the ...
Acute myeloid leukaemia ( AML ) is an aggressive and devastating blood cancer. It predominantly affects people over 60 and is one of the most common adult leukaemias in the Western World. The current ...
The FDA ( Food and Drug Administration ) has approved Velcade ( Bortezomib ) for the retreatment of adult patients with multiple myeloma who had previously responded to Bortezomib therapy and relapsed ...
The FDA ( Food and Drug Administration ) has approved a supplemental New Drug Application ( sNDA ) for the once-daily use of Promacta ( Eltrombopag; Europe: Revolade ) in patients with severe aplastic ...
The European Commission ( EU ) has approved the use of Avastin ( Bevacizumab ) in combination with Paclitaxel, Topotecan, or Pegylated liposomal doxorubicin chemotherapy as a treatment for women with ...
The FDA ( Food and Drug Administration ) has granted priority review designation for Ivabradine for the treatment of chronic heart failure ( HF ). Ivabradine is an oral drug that inhibits the If cu ...
The Food and Drug Administration ( FDA ) has approved a supplement to expand the indication for Lumizyme ( Alglucosidase alfa ). Lumizyme manufactured at the 4000L scale is now indicated for all Pompe ...
The FDA ( Food and Drug Administration ) has approved Cerdelga ( Eliglustat ) for the long-term treatment of adult patients with the type 1 form of Gaucher disease, a rare genetic disorder. Gaucher d ...
The FDA ( Food and Drug Administration ) has approved a Supplemental New Drug Application ( sNDA ) for Eliquis ( Apixaban ) for the treatment of deep vein thrombosis ( DVT ) and pulmonary embolism ( P ...
Paracetamol ( Acetaminophen ) poisoning is common worldwide. It is treated with intravenous Acetylcysteine, but the standard regimen is complex and associated with frequent adverse effects related to ...
A retrospective cohort study has evaluated the effect of anesthesia type on the risk of in-hospital mortality among adults undergoing hip fracture surgery in the United States. Participants were 73 ...
The objective of a study was to describe rates and risk factors for prolonged postoperative use of opioids in patients who had not previously used opioids and undergoing major elective surgery. The ...
Eliquis ( Apixaban ) is an oral selective Factor Xa inhibitor. By inhibiting Factor Xa, a key blood clotting protein, Apixaban decreases thrombin generation and blood clot formation. Eliquis is ap ...
Stivarga ( Regorafenib ) has been approved by the European Commission ( EC ) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors ( GIST ) who progressed ...
Eylea ( Aflibercept ) injection has been approved by the European Commission for the treatment of visual impairment due to diabetic macular edema ( DME ). Diabetetic macular edema is the leading caus ...
Kalydeco ( Ivacaftor ) is the first medicine to treat the underlying cause of cystic fibrosis in people with specific mutations in the CFTR gene. Known as a CFTR potentiator, Ivacaftor is an oral me ...
Hydroxychloroquine ( Plaquenil ) is indicated for the treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and malaria ( acute attacks and suppressive treatment ). Hypoglyce ...
